Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pin Zhang

Showing results (281-290 of 373) with videos related to

Pageof 38
Sort By:
Zhonghua Yi Xue Za Zhi|January 19, 2013
[Chinese HER2 positive early breast cancer trastuzumab adjuvant therapy: preliminary outcomes]Pin Zhang, Shi-ying Yu, Zhen-zhou Shen, et al.
Nature Immunology|February 8, 2011
Control of the development of CD8αα+ intestinal intraepithelial lymphocytes by TGF-βJoanne E Konkel, Takashi Maruyama, Andrea C Carpenter, et al.
The Oncologist|June 20, 2023
Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I TrialJunning Cao, Hongqian Guo, Dongmei Ji, et al.
Molecular Immunology|November 14, 2009
Reoxygenation of hypoxia-differentiated dentritic cells induces Th1 and Th17 cell differentiationQun Wang, Chunmei Liu, Faliang Zhu, et al.
Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban|July 5, 2016
Thymosin β4 impeded murine stem cell proliferation with an intact cardiovascular differentiationLi Nie, Shi-Jun Gao, Ya-Nan Zhao, et al.
International Journal of Cancer|July 7, 2018
Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in ChinaBo Lan, Fei Ma, Shanshan Chen, et al.
Cancer Research|July 9, 2009
Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathwayYansong Bian, Anita Terse, Juan Du, et al.
Breast (Edinburgh, Scotland)|September 4, 2024
Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapyLei Ji, Xi Chen, Xiaoyan Qian, et al.
Cancer Management and Research|June 20, 2019
Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysisYiqun Han, Jiayu Wang, Weiming Liu, et al.
Oncotarget|July 16, 2016
SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancerAnjie Zhu, Peng Yuan, Feng Du, et al.
Pageof 38

Showing results (281-290 of 373) with videos related to

Sort By:
Pageof 38
Zhonghua Yi Xue Za Zhi|January 19, 2013
[Chinese HER2 positive early breast cancer trastuzumab adjuvant therapy: preliminary outcomes]Pin Zhang, Shi-ying Yu, Zhen-zhou Shen, et al.
Nature Immunology|February 8, 2011
Control of the development of CD8αα+ intestinal intraepithelial lymphocytes by TGF-βJoanne E Konkel, Takashi Maruyama, Andrea C Carpenter, et al.
The Oncologist|June 20, 2023
Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I TrialJunning Cao, Hongqian Guo, Dongmei Ji, et al.
Molecular Immunology|November 14, 2009
Reoxygenation of hypoxia-differentiated dentritic cells induces Th1 and Th17 cell differentiationQun Wang, Chunmei Liu, Faliang Zhu, et al.
Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban|July 5, 2016
Thymosin β4 impeded murine stem cell proliferation with an intact cardiovascular differentiationLi Nie, Shi-Jun Gao, Ya-Nan Zhao, et al.
International Journal of Cancer|July 7, 2018
Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in ChinaBo Lan, Fei Ma, Shanshan Chen, et al.
Cancer Research|July 9, 2009
Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathwayYansong Bian, Anita Terse, Juan Du, et al.
Breast (Edinburgh, Scotland)|September 4, 2024
Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapyLei Ji, Xi Chen, Xiaoyan Qian, et al.
Cancer Management and Research|June 20, 2019
Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysisYiqun Han, Jiayu Wang, Weiming Liu, et al.
Oncotarget|July 16, 2016
SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancerAnjie Zhu, Peng Yuan, Feng Du, et al.
Pageof 38